Kaizen Financial Strategies

Position in GILD — Gilead Sciences, Inc.

CIK 1842013 CAMPBELL, CA

Position in GILD

as of Jun 30, 2026 · filed Jul 30, 2026 Compact

Position Value

$351,730

+$30,065 QoQ

Shares Held

2,784

+20.6% QoQ

Ownership

0.000%

of shares outstanding

% of Portfolio

0.32%

of 13F equity value

Holder Rank

#1,566

of 2,266 holders

Holding Since

Dec 2024

7 quarters on record

Voting authority Sole 0% Shared 0% None 100%

Healthcare · as of Jun 30, 2026

Kaizen Financial Strategies holds $4,120,314 across 6 Drug Manufacturers - General names. GILD ranks #4 (8.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	LLY	ELI LILLY & Co	1,464	$1,755,965
2	ABBV	AbbVie Inc.	4,092	$1,029,710
3	AMGN	Amgen Inc	1,393	$504,433
4	GILD	Gilead Sciences, Inc. This page	2,784	$351,730
5	MRK	Merck & Co., Inc.	2,010	$258,285
6	JNJ	Johnson & Johnson	867	$220,191

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$351,730	2,784	+20.6%	Shares	Sole	2026-07-30
2026-03-31	$321,665	2,308	+2.1%	Shares	Sole	2026-05-01
2025-12-31	$277,515	2,261	+0.3%	Shares	Sole	2026-01-21
2025-09-30	$250,305	2,255	-7.7%	Shares	Sole	2025-11-12
2025-06-30	$270,855	2,443	+10.0%	Shares	Sole	2025-08-08
2025-03-31	$248,751	2,220	-7.8%	Shares	Sole	2025-04-09
2024-12-31	$222,334	2,407	—	Shares	Sole	2025-02-14
No filing history on record for this holder in this stock.